GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bone Biologics BBLG · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.33

-0.63%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bone Biologics

From its filings with the US Securities and Exchange Commission

SEC filings

Bone Biologics is based in Burlington, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BBLG. The SEC classifies its business as orthopedic, prosthetic & surgical appliances & supplies. In the fiscal year to 31 December 2020, it reported revenue of $1.07bn.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
27 Nov 2015
Employees
2
Head office
2 BURLINGTON WOODS DRIVE,, BURLINGTON, MA, 01803
Incorporated in
DE
Classification
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Bruce StroeverIndependent Chairman of the Board$104,089
  • Mr. Jeffrey FrelickPresident, Chief Executive Officer$426,269
  • Ms. Deina WalshChief Financial Officer$263,136
  • Dr. Siddhesh AngleIndependent Director$94,089
  • Mr. Robert GagnonIndependent Director$94,089
  • Mr. Phillip MeikleIndependent Director$89,089

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Bone Biologics Corp focuses on NELL-1 for spinal fusion and bone regeneration in the Health Care sector.
  • NELL-1/DBM Fusion Device targets spine implants and non-union trauma cases with osteopromotive properties.
  • The company's platform technology uses recombinant human protein NELL-1 for bone void fillers and skeletal growth control.

Weaknesses

  • Bone Biologics Corp employs only 2 full-time employees in Burlington, Massachusetts.
  • The company's IPO on 27 November 2015 indicates limited market presence and resources.
  • NELL-1 development relies on laboratory and animal research without commercialized products.

Opportunities

  • NELL-1/DBM Fusion Device addresses osteoporosis treatment needs in the growing Health Care market.
  • The recombinant protein NELL-1 shows potential for expanding applications in skeletal regeneration fields.
  • Bone Biologics Corp can leverage platform technology for new medical device applications.

Threats

  • Bone Biologics Corp faces competition from established biotechnology firms in the Health Care sector.
  • The lack of commercialized products may delay market entry and revenue generation.
  • Regulatory approval processes for medical devices could delay product launches and market adoption.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.